INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market saleVerified data

Stueland Katherine sold WGS

Director, CHIEF EXECUTIVE OFFICER · GeneDx Holdings Corp. · Class A Common Stock

Side
SELL
Value
$301K
Shares
3,039
Price
$99
Executed
Sep 16, 2026
Disclosed
Sep 18, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 16 executedSep 18, 2026 disclosed

WGS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
28/ 100 · ROUTINE
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+7 / 25

    $301K reported value · 2.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · WGS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    18.8K sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    14
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    7,197 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    22
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$14K
    148 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    6
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    7,197 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    22
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$55K
    586 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    25
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$155K
    1,648 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    21
    FT
    Fuchs ThomasDirector
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    1,146 sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    22
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$144K
    1,470 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    28
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$407K
    4,141 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FT
    Fuchs ThomasDirector
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    1,146 sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    22
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$107K
    1,079 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    25
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$148K
    1,525 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    19
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$4,961
    52 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    18.8K sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    22
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$52K
    541 sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    5
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    6,547 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    6,547 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    14
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    2,462 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    6
    FK
    Feeley KevinCHIEF FINANCIAL OFFICER
    WGSGeneDx Holdings Corp.
    Option exercise
    		M—
    2,462 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    28
    SK
    Stueland KatherineDirector, CHIEF EXECUTIVE OFFICER
    WGSGeneDx Holdings Corp.
    Open-market sale
    		SELL$311K
    3,692 sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001689575-26-000032
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 16, 2026
    Published
    Sep 18, 2026
    Ingested by INSIDER
    Nov 5, 02:16 UTC
    Last re-read
    Nov 5, 02:16 UTC

    Extracted facts

    Filer
    Stueland Katherine
    Role
    Director, CHIEF EXECUTIVE OFFICER
    Transaction
    Open-market saleAs filed: “S”
    Asset
    GeneDx Holdings Corp.
    Ticker
    WGS
    Shares
    3,039
    Price per share
    $99
    Value
    $300,846
    Execution date (reported)
    Sep 16, 2026
    Owned after transaction
    115.5K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 3,039
    • Price: $98.995

    = $300,846

    What this establishes

    Stueland Katherine filed this Form 4 reporting a open-market sale of WGS on Sep 16, 2026. It became public on Sep 18, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CHIEF EXECUTIVE OFFICER
    Stueland Katherinecik:0001689575
    Issuer
    GeneDx Holdings Corp.cik:0001818331

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.